Funded Projects › HORIZON
FLUniversal · Intranasal, rapid-acting vaccine for all seasonal and pandemic influenza viruses
Researchers worldwide have been working to develop a universal flu vaccine, but no breakthrough has yet been achieved. FLUniversal is not ""another costly universal flu project"". It is an opportunity to create a genuine universal flu vaccine that will set the standard for rapid, efficient vaccine development, and generate know-how and tools to develop next-generation vaccines. We plan to exploit our increased understanding of molecular mechanisms of influenza infection and immunity to develop a vaccine effective against all flu virus strains. Our innovation uses genetically modified flu strains administered intranasally in a prime-boost regimen. This approach rapidly induces interferon and broadly cross-neutralising antibodies in the nasal passages and a systemic immune response directed to the conserved HA stalk. Proof of concept for universal protection was demonstrated in the ferret
Consortium · 8 organisations
Zafiro Business Solutions Korlatolt Felelossegu Tarsasag
HU · €348,125
ACADEMISCH ZIEKENHUIS LEIDEN
NL · €1,042,789
MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY
UK
STATENS SERUM INSTITUT
DK · €310,701
VISMEDERI SRL
IT · €496,198
STICHTING CENTRE FOR HUMAN DRUG RESEARCH
NL · €3,147,036
MEDITOX S.R.O
CZ · €382,500
VIVALDI BIOSCIENCES AG
AT · €1,840,439
Research fields
← Find collaborators and more funded projects
Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.